17 unchanged sentences
The stock price performance of the following graph is not necessarily indicative of future stock price performance.
−Removed: Company / Index
−Removed: Base Period 12/31/2014
+Added: Company / Index Base Period 12/31/2015 3/31/2016 6/30/2016 9/30/2016 12/31/2016
Precigen, Inc.
+Added: $ 100.00 $ 112.40 $ 81.63 $ 92.94 $ 80.60
S&P 500 Index 100.00 101.35 103.84 107.84 111.96
N asdaq Biotechnology Index
+Added: 100.00 77.12 76.25 85.78 78.65
Company / Index 3/31/2017 6/30/2017 9/30/2017 12/31/2017 3/31/2018 6/30/2018 9/30/2018 12/31/2018
Precigen, Inc.
+Added: $ 66.41 $ 80.72 $ 63.70 $ 38.60 $ 51.36 $ 46.71 $ 57.70 $ 21.91
S&P 500 Index 118.76 122.43 127.92 136.42 135.38 140.03 150.83 130.44
2 unchanged sentences
Precigen, Inc.
+Added: $ 17.62 $ 25.67 $ 19.17 $ 18.36 $ 11.39 $ 16.72 $ 11.73 $ 34.18
S&P 500 Index 148.24 154.62 157.24 171.50 137.89 166.22 181.06 203.06
2 unchanged sentences
(a) Sales of Unregistered Securities
−Removed: From January 1, 2019 through December 31, 2019 , we issued 1,606,062 unregistered shares of our common stock as payment under the services agreement entered into and effective as of November 1, 2015, as amended, by and between us and Third Security as previously discussed in our Current Report on Form 8-K filed on April 22, 2019.
−Removed: We issued the above referenced shares of common stock in reliance on exemptions from registration under Section 4(a)(2) of the Securities Act.
(b) Use of Proceeds
10 unchanged sentences
Year Ended December 31,
+Added: 2020 2019 2018 2017 2016
(In thousands, except share and per share amounts)
11 unchanged sentences
Weighted average shares outstanding, basic and diluted 167,065,539 154,138,774 129,521,731 119,998,826 117,983,836
+Added: 2020 2019 2018 2017 2016
(In thousands)
8 unchanged sentences
Noncontrolling interests — — 15,867 12,914 9,011
−Removed: Revenues and deferred revenue in 2019 and 2018 are accounted for under Accounting Standards Codification, or ASC, Topic 606, Revenue from Contracts with Customers , or ASC 606, and revenues and deferred revenue prior to 2018 are accounted for under ASC 605, Revenue Recognition , or ASC 605.
+Added: Total equity 67,174 71,711 378,722 546,545 569,248
+Added: (1) Revenues and deferred revenue in 2020, 2019, and 2018 are accounted for under ASC Topic 606, Revenue from Contracts with Customers , or ASC 606, and revenues and deferred revenue prior to 2018 are accounted for under ASC 605, Revenue Recognition , or ASC 605.
We adopted ASC 606 on January 1, 2018 using the modified retrospective method, which applies the changes in accounting prospectively and does not restate prior periods.
2 unchanged sentences
In conjunction with the ZIOPHARM License Agreement in 2018, all of our ZIOPHARM preferred shares were returned to ZIOPHARM.
−Removed: See "Notes to the Consolidated Financial Statements - Notes 10 and 11 " for discussions of impairment losses on long-lived assets recognized in 2019.
+Added: See "Notes to the Consolidated Financial Statements - Notes 10 and 11" for discussions of impairment losses on goodwill and other noncurrent assets recognized in 2020 and 2019.
(3) In 2018, we completed a registered underwritten public offering of $200,000 aggregate principal amount of Convertible Notes.
−Removed: Other liabilities include $8,801 and $15,629 of deferred consideration as of December 31, 2016 and 2015 , respectively.
+Added: (4) Other liabilities include $8,801 of deferred consideration as of December 31, 2016.
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.